Medtronic’s Companion Medical Acquisition: Exploring the Impetus with MDT's Mike Hill

article image

Medtronic’s latest tuck-in acquisition in the diabetes space, smart insulin pen company Companion Medical, gets Medtronic in on the “ground floor” of a huge and largely untapped growth opportunity, according to Mike Hill, VP of Marketing Analytics and Operations for Medtronic diabetes. What’s more, it could help the company inch toward a more collaborative diabetes business model.

In mid-August, Medtronic plc announced that it had reached a deal to acquire privately held smart insulin pen company Companion Medical for an undisclosed amount, taking Medtronic’s diabetes business in a new direction. Companion’s InPen system—the first smart insulin pen to receive FDA clearance (in 2016)—combines a Bluetooth-enabled insulin pen that automatically tracks insulin doses with a mobile app that monitors trends, keeps track of missed doses, sends dosing reminders, and calculates appropriate doses based on meal estimations.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: